Thanks, Josh. I'd like to start by sharing some thoughts on the M&A environment and how that's impacting activity in our portfolio. As we've discussed for several quarters, the M&A market has yet to deliver the meaningful rebound that many had anticipated in 2025. This muted transactional environment is clearly reflected in the leveraged loan market where M&A-related loan volume was down approximately 31% in the second quarter compared to the first, and second quarter loan volume marked its lowest levels since the fourth quarter of 2023. From our perspective, a meaningful reacceleration and M&A requires a catalyst for 1 of 3 areas: economic growth, interest rates or time. Given the prevailing uncertainty around trade policy, a surge in near-term growth appears unlikely. And the forward curve suggests rates will remain higher for longer. This leaves time as the most important factor. In an environment of slower growth and elevated rates, sponsors and management teams need a longer runway for portfolio company earnings to grow and generate an appropriate return on investments. While we can't predict the future, we estimate maybe the timing of M&A activity taking an inspiration from the Hubbert peak theory, which was used in the 1950s to estimate when U.S. oil production would peak. Utilizing data sourced from PitchBook, the [ medium ] buyout multiple at peak levels in 2021 has declined roughly 3 turns compared to the medium for closed buyout deals year-to-date. If we assume no multiple compression from the peak in 2021 and an average annual EBITDA growth rate of approximately 9%, consistent with historical S&P earnings growth, it would take approximately 4 to 5 years for a buyer to earn an appropriate multiple of money on their investment. If we apply the same assumptions, but including the rerating of multiples since the rate hiking cycle, this lengthens the time line to 6 to 7 years, implying an additional 2 years needed to grow earnings until an appropriate multiple of money is achieved. Based on our analysis, the earlier wave of investments from the pre-COVID vintages are now approaching the 6- to 7-year mark, which should moderately increase M&A activity in the next few quarters. As for the record-setting post-COVID, pre rate hiking vintages of 2021 and early 2022, which we estimate make up more than 40% of the current private equity net asset value, sellers need 6 to 8 additional quarters to reach an acceptable multiple of money, implying a further delay of the broad-based return of M&A activity that many are predicting. We recognize there are additional factors at play, and this time line will vary for different segments of the market. For example, investment-grade M&A is likely the first to return given the favorable regulatory environment. These businesses are also less levered compared to non-investment-grade companies, which means they have less sensitivity to interest rates. While the widespread return of M&A in our markets remains a future prospect, we have observed a noticeable shift in market sentiment beginning in late June and strengthening through July. In addition to some green shoots related to the buy-and-bill strategies, we have more notably seen a pickup in non-M&A-related activity within sponsored portfolios, such as duration management transactions. We expect these types of financings to be a prominent theme in the second half of the year as sponsors work to optimize their portfolio of companies in preparation for an improved exit environment. We believe we are very well positioned to provide the kind of complex bespoke capital solutions these situations require, creating attractive risk-adjusted returns for our shareholders. Turning now to activity in the second quarter. We provided total commitments of $289 million and total fundings of $209 million across 13 new investments and 4 upsizes to existing portfolio companies. To characterize our origination activity in Q2, approximately 30% of our commitments were sourced outside the sponsor channel. The remaining 70% came through the traditional sponsor-backed finance market, where we will leverage our deep relationships and platform scale to deploy capital into investments that are on an appropriate risk-adjusted return for our business. An example of our nontraditional transactions in Q2 is our direct-to-company investment in Ingenovis Health. This was an accounts receivable securitization financing, where the combination of our deep knowledge and specific health care themes, combined with the long-standing track record in asset-based loans, created a unique investment opportunity for SLX shareholders. With the resources in place across the Sixth Street platform, including dedicated ABL and health care teams, we have the ability to source and underwrite these off-the-run transactions that diversify our assets as well as our return profile relative to the sector. Another differentiated investment in our portfolio is Caris Life Sciences. As a reminder, we made initial debt and equity-linked investment in Caris in 2018 and subsequent equity-linked investments in 2020 and 2021. We fully exited our debt security in 2023, and the company recently completed an IPO in June. We still hold an equity position today, which is valued quarterly based on the company's closing stock price on the last day of the quarter. While equity positions are a small part of our overall portfolio, our ability to embed potential incremental economics into our business through unique thematic sourcing and disciplined underwriting serves as a competitive advantage for our shareholders. I'd like to spend a moment providing an update on one of our existing portfolio companies, Lithium Technologies that had previously been on nonaccrual status. During Q2, we navigated their sale process and restructuring of the business, working closely with the new sponsor to negotiate and drive an outcome. As a result of the restructuring, we hold a smaller loan that is paying cash interest and an earn-out equity security. This transaction had no material impact on our net asset value in Q2 as the realization of our original investment was consistent with our valuation as of March 31. Lithium has therefore been removed from nonaccrual status following the restructuring. Moving on to repayment activity. The second quarter marked the third consecutive quarter of elevated payoffs. Total repayments in Q2 were $389 million. This repayment activity contributed to another strong quarter of activity-based fee income, excluding other income totaling $0.11 per share in Q2 relative to our 3-year historical average of $0.05 per share. The repayment activity we experienced during the quarter was driven by a mix of refinancings and M&A activity. Of the exits that involve refinancing transactions, the majority were completed at lower investment spreads. Our portfolio continues to reflect our disciplined capital allocation as only 6.2% of our investments by fair value as of quarter end had a contractual spread of 500 basis points or below. While we don't have the comparable Q2 peer data set available yet, this is nearly 5x less than the average of 29% of public BDC portfolio spreads of 500 basis points or below as of March 31. A large portion of our payoffs during the quarter came from older pre-2022 vintages, reducing our exposure to these assets to 29% of the portfolio by cost. This compares to 59% or roughly double pre-2022 vintage exposure for the public BDC sector average as of March 31. We view this as a positive differentiator for our business as it reflected greater exposure to newer vintage assets that were originated following the commencement of the rate hiking cycle in early 2022. Given this greater exposure to new vintage assets, 37% of our exits were post-2022 investments, resulting in an incremental economics of shareholders driven by prepayment fees. Moving on to the portfolio metrics and yield. Despite recent competitive dynamics, we remain committed to high documentation standards that provide robust downside protection. At quarter end, we maintained effective voting control of 78% of our debt investments, an average of 2 financial covenants, consistent with historical levels. After managing prepayment risk, the fair value of our portfolio as a percentage of call protection is 94.1%, which means that we have protection in the form of additional economics that would flow through net investment income should our portfolio get repaid in the near term. As of June 30, the weighted average total yield on our debt and income-producing securities at amortized cost was 12.0% compared to 12.3% as of March 31. Given the meaningful payoff activity we experienced in Q2, the decline primarily reflects payoffs of higher- yielding assets exceeding the yields of new investments funded during the quarter. While credit spreads have remained competitive in Q2, our omnichannel sourcing capabilities enabled us to put capital to work in a disciplined manner demonstrated by a weighted average spread on new first lien investments of 652 basis points, which compares to a spread of 533 basis points on new issued first lien loans for the BDC peers in Q1, as Josh mentioned earlier. Moving on to the portfolio composition and key credit staff across our core borrowers for whom these metrics are relevant, we continue to have conservative weighted average attachment and detachment points of 0.3x and 5.0x, respectively, and our weighted average interest coverage remained consistent at 2.1x. As of Q2 2025, the weighted average revenue and EBITDA of our core portfolio of companies was $377 million and $114 million, respectively. Median revenue and EBITDA was $147 million and $46 million, respectively. Finally, overall portfolio performance is strong with weighted average rating of 1.10 on a scale of 1 to 5 with 1 being the strongest. The Lithium restructuring resulted in an improvement in nonaccruals quarter-over-quarter from 1.2% of the portfolio at fair value to 0.6%. As of June 30, we have 2 portfolio companies on nonaccrual status. With that, I'd like to turn it over to my partner, Ian, to cover our financial performance in more detail.